APLLTD Panoramica delle azioni Alembic Pharmaceuticals Limited sviluppa, produce e commercializza prodotti farmaceutici in India e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Alembic Pharmaceuticals Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Alembic Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione ₹1,050.65 Massimo di 52 settimane ₹1,303.90 Minimo di 52 settimane ₹787.55 Beta 0.71 Variazione di 1 mese -4.43% Variazione a 3 mesi -15.46% Variazione di 1 anno 29.85% Variazione a 3 anni 28.46% Variazione a 5 anni 88.20% Variazione dall'IPO 2,100.31%
Notizie e aggiornamenti recenti
Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% Dec 05
Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts Nov 10
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Nov 08
Alembic Pharmaceuticals Limited Announces Superannuation of Vipul Gandhi, Head - Business Development - Formulations Nov 07
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for its Abbreviated New Drug Application Diltiazem Hydrochloride Extended-Release Capsules Oct 21
Alembic Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 07, 2024 Oct 18 Vedi altri aggiornamenti
Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% Dec 05
Earnings Miss: Alembic Pharmaceuticals Limited Missed EPS By 5.6% And Analysts Are Revising Their Forecasts Nov 10
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Nov 08
Alembic Pharmaceuticals Limited Announces Superannuation of Vipul Gandhi, Head - Business Development - Formulations Nov 07
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for its Abbreviated New Drug Application Diltiazem Hydrochloride Extended-Release Capsules Oct 21
Alembic Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 07, 2024 Oct 18
Now 21% overvalued after recent price rise Oct 15
Alembic Pharmaceuticals Limited Announces USFDAFinal Approval for Lamotrigine Extended-Release Tablets Usp, 200 mg, 250 mg, and 300 mg Oct 06
Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price Sep 25
Alembic Pharmaceuticals Limited Appoints Mr. Sudhakar Pandiyan as Head - Technical Operations Sep 16
Investor sentiment improves as stock rises 17% Sep 10
Price target increased by 7.2% to ₹1,056 Sep 10
Now 25% overvalued after recent price rise Sep 09
Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt? Sep 03
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration for Its Abbreviated New Drug Application Betamethasone Valerate Foam, 0.12% Aug 24
Alembic Pharmaceuticals Limited Announces Resignation of Nilesh Shah as Head Legal Aug 22
Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now Aug 13
First quarter 2025 earnings: EPS and revenues miss analyst expectations Aug 09
Alembic Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 08, 2024 Jul 25
Alembic Pharmaceuticals Receives USFDA Final Approval for Fluphenazine Hydrochloride Tablets USP, 1 Mg, 2.5 Mg, 5 Mg, and 10 Mg Jul 24
Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher Jul 20
Alembic Pharmaceuticals Limited Announces USFDA Tentative Approval for Selexipag for Injection, 1,800 Mc/Vial Jul 12
Alembic Pharmaceuticals Announces Usfda Final Approval for Bromfenac Ophthalmic Solution, 0.07% Jul 09
Upcoming dividend of ₹11.00 per share Jul 08
Alembic Pharmaceuticals Limited Receives USFDATentative Approval for Ivosidenib Tablets 250 Mg Jul 04
Now 21% overvalued Jul 01
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Jun 25
Dividend increased to ₹11.00 Jun 24
Alembic Pharmaceuticals Limited, Annual General Meeting, Jul 22, 2024 Jun 10
Alembic Pharmaceuticals Limited Announces Superannuation of Chandrahas Shetty as President-Human Resources (India Branded Business) Jun 08
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly Jun 03
Now 20% overvalued May 29
Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying? May 11
Full year 2024 earnings released: EPS: ₹31.33 (vs ₹17.40 in FY 2023) May 10 Alembic Pharmaceuticals Limited Receives Various US Food & Drug Administration (Tentative or Final) Product Approvals
Alembic Pharmaceuticals Limited to Report Q4, 2024 Results on May 09, 2024 Apr 20
Price target increased by 8.4% to ₹933 Apr 12
Consensus EPS estimates increase by 14% Feb 12
Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates Feb 08
Price target increased by 7.4% to ₹827 Feb 07
Third quarter 2024 earnings: Revenues in line with analyst expectations Feb 06
Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25% Jan 21
Alembic Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 05, 2024 Jan 19
Investor sentiment improves as stock rises 17% Jan 15
Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment? Jan 05 Alembic Pharmaceuticals Receives Various Us Food & Drug Administration Product Approvals
Alembic Pharmaceuticals Limited Appoints Pradeep Chakravarty as Head - Global Quality Dec 04
Alembic Pharmaceuticals Limited Announces Management Changes Nov 29
Alembic Pharmaceuticals Limited Announces Management Changes Nov 28
Alembic Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 07, 2023 Oct 17
Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly Sep 27
Alembic Pharmaceuticals Limited Announces Resignation of Jesal Shah as Head - Strategy Sep 02
Alembic Pharmaceuticals Limited Announces That Mr. Nilesh Wadhwa, Head - International Business & Strategy (Formulations Business Development Division), Is Designated as Senior Management Personnel Aug 22
Price target increased by 10% to ₹659 Aug 07
First quarter 2024 earnings released: EPS: ₹6.14 (vs ₹3.35 loss in 1Q 2023) Aug 05
Alembic Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 04, 2023 Jul 24
Upcoming dividend of ₹8.00 per share at 1.2% yield Jul 21
Full year 2023 earnings: EPS exceeds analyst expectations Jun 24
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly Jun 09
Alembic Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023 Jun 06
Full year 2023 earnings: EPS exceeds analyst expectations May 07 Alembic Pharmaceuticals Limited Approves the Appointment of Jai Diwanji as an Independent Director
A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Apr 13
Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment? Feb 22
Consensus EPS estimates fall by 19% Feb 10
Third quarter 2023 earnings released: EPS: ₹6.20 (vs ₹8.98 in 3Q 2022) Feb 04
Consensus EPS estimates fall by 11% Feb 03
Alembic Pharmaceuticals Limited Announces Company Secretary and Compliance Officer Changes Feb 02
Alembic Pharmaceuticals Receives USFDA Tentative Approval for Acalabrutinib Capsules, 100 Mg Jan 20
Alembic Pharmaceuticals Limited Receives Final Approval from the US Food & Drug Administration Jan 07
Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate Jan 04
Now 20% undervalued after recent price drop Dec 20
Alembic Pharmaceuticals Limited Receives USFDA Final Approval for DesonideCream, 0.05% Dec 11
Alembic Pharmaceuticals Receives USFDA Final Approval for Diclofenac Sodium Topical Solution USP, 2% w/w Dec 01
Alembic Pharmaceuticals Receives USFDA Final Approval for Nifedipine Extended-Release Tablets USP, 30 Mg, 60 Mg and 90 Mg Nov 21
Consensus forecasts updated Nov 18
Insufficient new directors Nov 16
Alembic Pharmaceuticals Limited Receives US FDA Final Approval for Cyclophosphamide Capsules, 25 Mg and 50 Mg Nov 15
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 13
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now Nov 05
Investor sentiment improved over the past week Nov 03
Alembic Pharmaceuticals Receives Usfda Final Approval for Mesalamine Extended-Release Capsules Usp, 0.375 G Nov 03
Alembic Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 11, 2022 Nov 02
Alembic Pharmaceuticals Limited (Alembic) Receives Final Approval from the Us Food & Drug Administration Oct 29
Alembic Pharmaceuticals Limited Announces Successful Completion of USFDA Inspection at Alembic Pharmaceuticals' Bioequivalence Facility at Vadodara Oct 27
Alembic Pharmaceuticals Limited, Annual General Meeting, Nov 11, 2022 Sep 16
Alembic Pharmaceuticals Limited Receives; U.S. Food & Drug Administration Final Approval for Chlorthalidone Tablets USP, 25 Mg and 50 Mg Aug 29
Consensus EPS estimates fall by 28% Aug 11
Upcoming dividend of ₹10.00 per share Aug 10
Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden Aug 10
Price target decreased to ₹734 Aug 07
First quarter 2023 earnings released: ₹3.35 loss per share (vs ₹8.37 profit in 1Q 2022) Aug 05
Alembic Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 04, 2022 Jul 21
Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Jul 20
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Jun 22
Alembic Pharmaceuticals Receives US Food & Drug Administration Tentative Approval for Dasatinib Tablets, 20 Mg, 50 Mg, 70 Mg, 80 Mg, 100 Mg, and 140 Mg Jun 11 Rendimenti per gli azionisti APLLTD IN Pharmaceuticals IN Mercato 7D 1.4% 3.1% 0.5% 1Y 29.8% 36.2% 17.4%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: APLLTD ha avuto una performance inferiore rispetto al Indian Pharmaceuticals che ha registrato un rendimento 36.2 % nell'ultimo anno.
Rendimento vs Mercato: APLLTD ha superato il mercato Indian che ha restituito 17.4 % nell'ultimo anno.
Volatilità dei prezzi Is APLLTD's price volatile compared to industry and market? APLLTD volatility APLLTD Average Weekly Movement 4.5% Pharmaceuticals Industry Average Movement 5.9% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.1%
Prezzo delle azioni stabile: APLLTD non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di APLLTD è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Alembic Pharmaceuticals Limited sviluppa, produce e commercializza prodotti farmaceutici in India e a livello internazionale. L'azienda fornisce specialità medicinali di marca in varie aree terapeutiche, quali cardiologia, ginecologia, gastrologia, oftalmologia, dermatologia, nefrologia/urologia, ortopedia, antinfettivi, raffreddore e tosse, veterinaria e antidiabetici; formulazioni generiche in solidi orali, solidi orali e iniettabili per oncologia, iniettabili generici e prodotti oftalmici, dermatologia e sospensione orale; e ingredienti farmaceutici attivi. L'azienda esporta anche i suoi prodotti.
Mostra di più Alembic Pharmaceuticals Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Alembic Pharmaceuticals con la sua capitalizzazione di mercato? APLLTD statistiche fondamentali Capitalizzazione di mercato ₹206.52b Guadagni(TTM ) ₹6.47b Ricavi(TTM ) ₹63.57b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) APLLTD Conto economico (TTM ) Ricavi ₹63.57b Costo del fatturato ₹17.44b Profitto lordo ₹46.13b Altre spese ₹39.66b Guadagni ₹6.47b
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 32.90 Margine lordo 72.56% Margine di profitto netto 10.17% Rapporto debito/patrimonio netto 20.4%
Come si è comportato APLLTD nel lungo periodo?
Vedi performance storica e confronto Dividendi
1.0% Rendimento attuale del dividendo
35% Rapporto di remunerazione
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/02 21:12 Prezzo dell'azione a fine giornata 2025/01/02 00:00 Guadagni 2024/09/30 Guadagni annuali 2024/03/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Alembic Pharmaceuticals Limited è coperta da 25 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Sarabjit Nangra Angel Broking Private Limited null null Antique Stockbroking Ltd. Harith Ahamed Avendus Spark
Mostra 22 altri analisti 
